

April 1, 2025

**Notice Regarding Adjustment of 340B Prices for Select Products of SK Life Science, Inc.**

SK Life Science, Inc. has recalculated its 340B ceiling prices for the period from July 1, 2023, through June 30, 2024, which resulted in 340B price changes to the products and periods below, due to revisions made to the Medicaid pricing data. SK Life Science, Inc. has asked the Office of Pharmacy Affairs (OPA) within HRSA to post this Notice on the public website to ensure transparency by providing access to information about SK Life Science, Inc.'s recalculation affecting certain 340B Covered Entities for the impacted products.

SK Life Science, Inc. has evaluated purchases made during this refund period and determined the credit amount owed to each affected covered entity. The largest refund at the entity level is less than \$6.

NDC	NDC Description	340B Sales Periods
71699-0050-30	XCOPRI 50 MG TABLET	Q2 2024
71699-0200-30	XCOPRI 200 MG TABLET	Q3 2023

SK Life Science, Inc. routinely issues proactive refunds for each affected Covered Entity with a refund amount that is equal to or over \$50. SKLSI is committed to issuing a refund to any Covered Entity that was overcharged on a PHS purchase made for these two periods. If a Covered Entity believes they are due a refund, please contact SK Life Science, Inc at [gzhang@sklsi.com](mailto:gzhang@sklsi.com) by June 30, 2025. Please include in the subject line "340B Reimbursement" and include your entity's 340B ID. In addition, please include Invoice Date, Wholesaler Purchased from, Quantity Purchased, Invoiced Amount, and Purchase Invoice Number in the body of your email so that we can research your inquiry and reimburse, as necessary. Refund checks will be issued to the facility and match Federal Tax ID number.